Pharmaceutical Composition for Preventing or Treating Cancer Comprising Carnitine Acylcarnitine Carrier Inhibitor and Antitumor Agent

The present invention relates to a pharmaceutical composition comprising a carnitine acylcarnitine carrier (CAC) inhibitor and an anticancer agent for preventing or treating cancer, and an anticancer adjuvant. The composition comprising a CAC inhibitor and an anticancer agent according to the presen...

Full description

Saved in:
Bibliographic Details
Main Author KIM SOO YOUL
Format Patent
LanguageEnglish
Korean
Published 30.03.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to a pharmaceutical composition comprising a carnitine acylcarnitine carrier (CAC) inhibitor and an anticancer agent for preventing or treating cancer, and an anticancer adjuvant. The composition comprising a CAC inhibitor and an anticancer agent according to the present invention significantly reduced the growth of various cancer cells, compared to the single use of the CAC inhibitor or the anticancer agent and it was found that the combined administration of the CAC inhibitor and the anticancer agent had a synergic effect against cancer in a xenografted tumor animal model. Accordingly, the composition can be advantageously utilized as an effective combinational anticancer agent. 본 발명은 카르니틴 아실카르니틴 운반자(Carnitine Acylcarnitine Carrier: CAC) 억제제 및 항암제를 포함하는 암 예방 또는 치료용 약학적 조성물, 및 항암보조제에 관한 것이다. 본 발명의 카르니틴 아실카르니틴 운반자 억제제 및 항암제를 포함하는 조성물은 카르니틴 아실카르니틴 운반자 억제제 또는 항암제를 각각 단독으로 사용하는 경우에 비하여 다양한 암세포 성장을 유의적으로 감소시켰을 뿐만 아니라, 이종이식 종양 동물 모델에서도 카르니틴 아실카르니틴 운반자 억제제 및 항암제 병용투여에 따른 항암 시너지 효과를 확인하였다. 따라서, 본 발명의 조성물은 효과적인 병용 항암제로 유용하게 활용될 수 있다.
Bibliography:Application Number: KR20220120696